GSK PLC Stock Price, News & Analysis

GSK Consumer Healthcare announced new findings regarding the effects of osteoarthritis (OA) on morning routines, revealing that 67% of Americans with OA struggle to get out of bed due to pain. The study shows that OA significantly impacts daily life, with 56% of those employed reporting lateness to work and over half changing jobs because of pain. To support OA patients, GSK promotes Voltaren Arthritis Pain Gel, a topical NSAID alternative to oral pain relief, and is partnering with the Arthritis Foundation to match donations up to $100,000 this May for Arthritis Awareness Month.

GlaxoSmithKline (GSK) announced FDA approval for JEMPERLI (dostarlimab-gxly), a PD-1 blocking antibody, for treating adult patients with mismatch repair-deficient recurrent or advanced endometrial cancer post-platinum therapy. The approval, based on the GARNET trial, showed an overall response rate of 42.3% among 71 patients, with a durable response in 93.3% of responders for at least 6 months. The treatment is part of GSK's commitment to improving options for patients with this challenging cancer type.

GSK Consumer Healthcare has announced its commitment to reduce plastic in over 80 million Advil bottles by 20%, eliminating nearly 500,000 pounds of plastic waste. By 2022, nearly all Advil bottles will adopt this new sustainable barrier resin technology. This initiative aligns with GSK's broader sustainability goal of making all consumer product packaging recyclable or reusable by 2025. GSK also aims for net-zero climate impact by 2030, having joined the Ellen MacArthur Network to promote a circular economy for plastics.

Viome has appointed Dr. Emmanuel Hanon as Global Head of Research and Development, effective July 1. Dr. Hanon previously served over 20 years at GSK, including senior vice president of vaccine research. He oversaw 3,500 employees across 50 countries, contributing to various vaccine developments. Viome aims to leverage Hanon's expertise in therapeutics to enhance its precision medicine initiatives, focusing on chronic disease prevention through advanced data analytics. CEO Naveen Jain emphasized the importance of understanding root causes of diseases for healthcare transformation.

GSK Consumer Healthcare (GSK) announced a partnership with MLB champion Cody Bellinger as the face of its 'Change The Game' campaign for Flonase Allergy Relief. As the Official Allergy Relief Partner of MLB, Flonase targets allergy sufferers, highlighted by Bellinger, who deals with seasonal allergies during baseball season. The campaign will feature baseball-themed marketing across various media. Bellinger emphasizes the effectiveness of Flonase in managing his symptoms, advocating a 100% Money Back Guarantee for consumers.

GSK Consumer Healthcare (GSK) announced a partnership with MLB and World Series champion Cody Bellinger to promote Flonase Allergy Relief through the "Change The Game" campaign. As the Official Allergy Relief Partner of MLB, Flonase aims to address allergy challenges faced by athletes and fans, especially during baseball season. Bellinger, who suffers from seasonal allergies, emphasizes switching to Flonase for 24-hour relief. The campaign will leverage baseball-themed marketing across digital and retail channels, along with a 100% Money Back Guarantee for consumers.

Eli Lilly, Vir Biotechnology, and GlaxoSmithKline announced promising topline results from the Phase 2 BLAZE-4 trial, showing that the combination of bamlanivimab and VIR-7831 significantly reduced high viral loads in low-risk COVID-19 patients by 70% at day 7 compared to placebo. No related hospitalizations or deaths occurred by day 29. Preclinical data suggest the combination can combat resistant SARS-CoV-2 variants. An Emergency Use Authorization application for VIR-7831 has been submitted to the FDA, aiming to expedite its availability for COVID-19 treatment.

GSK Consumer Healthcare (GSK) announced the launch of TUMS Naturals, a new antacid that caters to consumer preferences for natural ingredients. This product expands TUMS' portfolio, which is the top heartburn relief medicine in the U.S., by offering alternatives free from artificial flavors and dyes. TUMS Naturals, containing Calcium Carbonate, is available in two fruity flavors and is designed to neutralize stomach acid quickly. The product aligns with consumer demand for natural health solutions and aims to provide effective relief from heartburn without compromising on quality.

GlaxoSmithKline (GSK) has launched the #TUMSBingoSweepstakes, an engaging digital bingo game coinciding with the BIG GAME on February 7, 2021. Participants can win a share of $55,000 in prizes, with the grand prize being $35,000. The game celebrates moments that induce heartburn, allowing fans to interactively enjoy the event. TUMS aims to combine entertainment with heartburn relief, with digital game boards updating in real-time during the game. This initiative follows their successful 2020 sweepstakes and aims to enhance viewer participation.